MX2017012506A - Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. - Google Patents
Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.Info
- Publication number
- MX2017012506A MX2017012506A MX2017012506A MX2017012506A MX2017012506A MX 2017012506 A MX2017012506 A MX 2017012506A MX 2017012506 A MX2017012506 A MX 2017012506A MX 2017012506 A MX2017012506 A MX 2017012506A MX 2017012506 A MX2017012506 A MX 2017012506A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- tissue
- vegf
- preparation
- eye diseases
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 7
- 238000002360 preparation method Methods 0.000 title abstract 6
- 208000030533 eye disease Diseases 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003102 growth factor Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 6
- 210000001519 tissue Anatomy 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000002137 anti-vascular effect Effects 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 210000003668 pericyte Anatomy 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica para prevenir y tratar enfermedades de los ojos, que comprende, como un ingrediente activo, una proteína de fusión en donde un péptido que penetra el tejido y una preparación del factor de crecimiento endotelial antivascular (anti-VEGF) se fusionan. Más particularmente, la presente invención se refiere a: una composición farmacéutica para prevenir y tratar enfermedades de los ojos, que comprende, como un ingrediente activo, una proteína de fusión en donde un péptido que penetra el tejido y una preparación anti-VEGF se fusionan; un método para preparar una preparación anti-VEGF, que supera la resistencia y tiene una eficacia mejorada, el método comprende los pasos de transformar una célula hospedera con un vector recombinante que comprende una secuencia de ácido nucleico que codifica una proteína de fusión en donde un péptido que penetra el tejido y una preparación anti-VEGF se fusionan, cultivar la célula, y recuperar una proteína de fusión de la célula; un método para tratar enfermedades del ojo, que comprende administrar una dosis efectiva de la proteína de fusión de acuerdo con la presente invención a un sujeto con tal necesidad; y el uso de la proteína de fusión de acuerdo con la presente invención para preparar un agente para tratar enfermedades del ojo. Comparada con preparaciones anti-VEGF convencionales, la composición de acuerdo con la presente invención se considera que tiene una eficacia mejorada y es capaz de usarse para el tratamiento de pacientes con resistencia a fármacos, mediante la inhibición de varios factores de crecimiento relacionados con los nuevos vasos sanguíneos, aparte de VEGF, y mediante la reducción de la cobertura del pericito. Además, dado que la habilidad de suministro de fármaco en el tejido coroideo se mejora cuando se lleva a cabo la inyección intraocular, la composición puede desarrollarse como gotas para los ojos reduciendo una dosis administrada o extendiendo un ciclo de administración, y mejorando la penetrabilidad ocular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150045684 | 2015-03-31 | ||
| PCT/KR2016/003254 WO2016159652A1 (ko) | 2015-03-31 | 2016-03-30 | 조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012506A true MX2017012506A (es) | 2018-06-27 |
| MX383971B MX383971B (es) | 2025-03-14 |
Family
ID=57004803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012506A MX383971B (es) | 2015-03-31 | 2016-03-30 | Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11052130B2 (es) |
| EP (2) | EP3973977A1 (es) |
| JP (1) | JP6836512B2 (es) |
| KR (1) | KR101846306B1 (es) |
| CN (1) | CN108348572B (es) |
| AU (1) | AU2016241499B2 (es) |
| BR (1) | BR112017020948A2 (es) |
| CA (1) | CA2981145C (es) |
| MX (1) | MX383971B (es) |
| RU (1) | RU2712623C2 (es) |
| WO (1) | WO2016159652A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10561707B2 (en) | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3973977A1 (en) | 2015-03-31 | 2022-03-30 | Ildong Pharm Co., Ltd. | Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
| EP3407846B1 (en) * | 2016-01-25 | 2021-09-22 | Technion Research & Development Foundation Limited | Composition comprising a semaphorin 3c or variant thereof for use in treating age-related macular degeneration |
| KR20200140817A (ko) | 2018-03-02 | 2020-12-16 | 코디악 사이언시스 인코포레이티드 | Il-6 항체 그리고 이의 융합 작제물 및 접합체 |
| MX421310B (es) | 2018-05-10 | 2025-03-14 | Regeneron Pharma | Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración |
| EP3808842A4 (en) * | 2018-06-14 | 2022-11-23 | Avixgen Inc. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEVERE COMPLEX IMMUNE DEFICIENCY WITH A CELL-PERFORMING PEPTIDE AND ADENOSINDEAMINASE FUSION PROTEIN |
| US20210068733A1 (en) * | 2019-09-06 | 2021-03-11 | United States Government As Represented By The Department Of Veterans Affairs | Methods and systems for self-administered measurement of critical flicker frequency (cff) |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN113384715B (zh) * | 2021-06-03 | 2023-08-04 | 上海市第十人民医院 | 一种含有细胞穿透肽融合蛋白的抗vegf药物及其制备方法和应用 |
| CN115927472A (zh) * | 2021-07-05 | 2023-04-07 | 武汉纽福斯生物科技有限公司 | 一种抗vegf抗体体内表达系统的构建和应用 |
| WO2024144099A1 (ko) * | 2022-12-27 | 2024-07-04 | 주식회사 넥스세라 | 안구 질환 치료를 위한 효율적인 약물 전달 플랫폼 |
| CN116785440A (zh) * | 2023-08-09 | 2023-09-22 | 天津医科大学总医院 | Sema4D抑制剂在制备预防和/或治疗脉络膜新生血管药物中的应用 |
| CN118108862B (zh) * | 2024-04-29 | 2024-08-09 | 上海鼎新基因科技有限公司 | 抗血管新生的融合蛋白及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5006651B2 (ja) | 2003-12-05 | 2012-08-22 | ブリストル−マイヤーズ スクウィブ カンパニー | ２型血管内皮増殖因子受容体の阻害剤 |
| US20070071756A1 (en) * | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| JP2010528647A (ja) | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| CN101951925A (zh) * | 2008-02-20 | 2011-01-19 | 建新公司 | 血管发生抑制 |
| FI121959B (fi) * | 2008-05-09 | 2011-06-30 | Pirjo Laakkonen | Aivokasvaimiin hakeutuva peptidi |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| PL2433953T3 (pl) * | 2009-05-20 | 2015-12-31 | Toray Industries | Peptydy o zdolności przenikania przez błonę komórkową |
| US10370245B2 (en) * | 2009-06-22 | 2019-08-06 | Sanford-Burnham Medical Research Institute | Methods and compositions using peptides and proteins with C-terminal elements |
| CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| MX349622B (es) * | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| ES2753135T3 (es) | 2012-05-07 | 2020-04-07 | Allergan Inc | Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| EP3000825A4 (en) * | 2013-05-23 | 2017-02-08 | Ajou University Industry-Academic Cooperation Foundation | Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein |
| EP2989714B1 (en) | 2013-09-19 | 2016-11-16 | Philips Lighting Holding B.V. | Compact power conversion device with continuous output regulation range |
| KR102157618B1 (ko) | 2013-10-21 | 2020-09-18 | 주식회사 아이티엘 | 서빙셀별로 듀플렉스 방식을 달리하는 무선 통신 시스템에서 통신을 수행하는 장치 및 그 방법 |
| EP3973977A1 (en) | 2015-03-31 | 2022-03-30 | Ildong Pharm Co., Ltd. | Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused |
-
2016
- 2016-03-30 EP EP21195152.0A patent/EP3973977A1/en not_active Withdrawn
- 2016-03-30 EP EP16773433.4A patent/EP3278810A4/en not_active Withdrawn
- 2016-03-30 AU AU2016241499A patent/AU2016241499B2/en not_active Ceased
- 2016-03-30 CN CN201680031204.9A patent/CN108348572B/zh active Active
- 2016-03-30 WO PCT/KR2016/003254 patent/WO2016159652A1/ko not_active Ceased
- 2016-03-30 RU RU2017137735A patent/RU2712623C2/ru active
- 2016-03-30 MX MX2017012506A patent/MX383971B/es unknown
- 2016-03-30 JP JP2017550872A patent/JP6836512B2/ja not_active Expired - Fee Related
- 2016-03-30 BR BR112017020948-9A patent/BR112017020948A2/pt not_active Application Discontinuation
- 2016-03-30 CA CA2981145A patent/CA2981145C/en active Active
- 2016-03-30 KR KR1020160038327A patent/KR101846306B1/ko not_active Expired - Fee Related
-
2017
- 2017-09-29 US US15/720,016 patent/US11052130B2/en not_active Expired - Fee Related
-
2021
- 2021-03-17 US US17/204,311 patent/US11738064B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108348572A (zh) | 2018-07-31 |
| MX383971B (es) | 2025-03-14 |
| AU2016241499A1 (en) | 2017-11-09 |
| CA2981145C (en) | 2021-05-11 |
| RU2712623C2 (ru) | 2020-01-30 |
| CN108348572B (zh) | 2021-06-29 |
| US11738064B2 (en) | 2023-08-29 |
| RU2017137735A3 (es) | 2019-09-11 |
| WO2016159652A1 (ko) | 2016-10-06 |
| RU2017137735A (ru) | 2019-04-30 |
| US20210220436A1 (en) | 2021-07-22 |
| JP2018515435A (ja) | 2018-06-14 |
| JP6836512B2 (ja) | 2021-03-03 |
| KR20160117329A (ko) | 2016-10-10 |
| AU2016241499B2 (en) | 2020-12-17 |
| EP3973977A1 (en) | 2022-03-30 |
| EP3278810A4 (en) | 2018-11-21 |
| BR112017020948A2 (pt) | 2018-07-10 |
| EP3278810A1 (en) | 2018-02-07 |
| KR101846306B1 (ko) | 2018-05-18 |
| US20180133288A1 (en) | 2018-05-17 |
| US11052130B2 (en) | 2021-07-06 |
| CA2981145A1 (en) | 2016-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP6438599B2 (ja) | 抗ｃｇｒｐ抗体製剤 | |
| WO2016042163A3 (en) | Ophthalmic drug compositions | |
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| US9044436B2 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| EA201991299A1 (ru) | Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| EA201790568A1 (ru) | Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| MY188825A (en) | High-concentration monoclonal antibody formulations | |
| MX2021012049A (es) | Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad. | |
| JP2016514132A5 (es) | ||
| JP2016528202A5 (es) | ||
| JP2016516016A5 (es) | ||
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| JP2016539921A5 (es) | ||
| WO2020097511A3 (en) | Messenger rna therapy for treatment of ocular diseases | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| RU2017128296A (ru) | Композиция для лечения бесплодия | |
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| MX379191B (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| HK1216007A1 (zh) | 人体生长激素和白蛋白的融合、制剂及其用途 | |
| RU2017126212A (ru) | Композиция |